Tadalafil
A 5-phosphodiesterase inhibitor with uses similar to sildenafil, used in the treatment of pulmonary hypertension (including in children: Takatsuki 2012), erectile dysfunction in men, Raynaud's syndrome and in other treatments due to its vasodilatory effect on smooth muscle.
Since the last update, we have not found published data on its excretion in breast milk.
Its high percentage of protein binding makes it unlikely that it will be transferred to milk in significant amounts, as in fact has been seen in another drug from the same therapeutic group, sildenafil.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Alternatives
- Sildenafil (Very Low Risk)
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Low Risk
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
High Risk
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
Writings
- تادالافيل (Arabic)
- Тадалафил (Cyrillic)
- 타달라필 (Chinese)
- タダラフィル (Japanese)
- Tadalafil (French)
- C22H19N3O4 (Molecular formula)
- (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-[3,4-(methylenedioxy)phenyl]pyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione (Chemical name)
References
- EMA. Tadalafilo. Ficha técnica. 2017 Full text (in our servers)
- EMA. Tadalafil. Drug Summary. 2017 Full text (in our servers)
- Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol. 2012Abstract Full text (link to original source)
- Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006Abstract Full text (link to original source)